Malignant brain tumors heavily increase the burden on the patients' quality of life and even survival. Despite standard treatments available, prognoses of malignant brain tumors remain poor. Glioblastoma, one of the most lethal variants, has a 5-year survival rate of less than 10%, thus calling for the need for novel treatments with great efficacy. In recent 10 years, immunotherapy showed impressive antitumor efficiency in the preclinical and clinical studies of brain cancer. These immunotherapeutic strategies include antibodies that target tumor cells or tumor tissue components, vaccines that introduce dendritic cells, engineered T cells such as chimeric antigen receptor (CAR)-T cell and TCR-T cell, oncolytic viruses that could induce tumor cell lysis and activate the immune system.
The progress of immunotherapy in high-grade glioma was limited, due to the invasive growth, immunosuppressive microenvironment, and uniquely tolerant site of origin. Nevertheless, recent studies have also made great progress on these substantial obstacles and developed effective and long-lasting immunotherapeutic strategies. For example, basic research explored and discussed the components of the brain tumor microenvironment as well as how they may contribute to treatment responses. In addition, clinical studies that aim to target the brain tumor microenvironment to lower the barrier of immunosuppression also showed clinical benefits.
The goal of this Research Topic is to provide a forum for basic and clinical research on the contribution of brain malignant tumor microenvironment components to the treatment response as well as to explore innovative immunotherapeutic strategies to lower the tumor microenvironment barrier. Topics of interest include but are not limited to immunotherapy and combination therapy against brain malignant tumors as well as basic research that improves the understanding and treatment of brain tumors. We welcome manuscripts from the following subtopics:
1, Mechanisms of malignant brain tumor (especially high-grade glioma) microenvironment components affecting the immune system and/or immunotherapeutic response.
2, Innovative immunotherapy strategies against brain malignant tumor.
3, Methods of targeting tumor microenvironment or counteracting the immunosuppression to improve immunotherapeutic responses of brain tumors
4, Clinical trial of advanced immunotherapy treatment on brain tumors (e.g., CAR-T, TCR-T, oncolytic virus, tumor vaccine, combination studies, etc)
NOTE: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation are considered out of the scope of this section. Experimental validations using cell lines only are not acceptable either.
Malignant brain tumors heavily increase the burden on the patients' quality of life and even survival. Despite standard treatments available, prognoses of malignant brain tumors remain poor. Glioblastoma, one of the most lethal variants, has a 5-year survival rate of less than 10%, thus calling for the need for novel treatments with great efficacy. In recent 10 years, immunotherapy showed impressive antitumor efficiency in the preclinical and clinical studies of brain cancer. These immunotherapeutic strategies include antibodies that target tumor cells or tumor tissue components, vaccines that introduce dendritic cells, engineered T cells such as chimeric antigen receptor (CAR)-T cell and TCR-T cell, oncolytic viruses that could induce tumor cell lysis and activate the immune system.
The progress of immunotherapy in high-grade glioma was limited, due to the invasive growth, immunosuppressive microenvironment, and uniquely tolerant site of origin. Nevertheless, recent studies have also made great progress on these substantial obstacles and developed effective and long-lasting immunotherapeutic strategies. For example, basic research explored and discussed the components of the brain tumor microenvironment as well as how they may contribute to treatment responses. In addition, clinical studies that aim to target the brain tumor microenvironment to lower the barrier of immunosuppression also showed clinical benefits.
The goal of this Research Topic is to provide a forum for basic and clinical research on the contribution of brain malignant tumor microenvironment components to the treatment response as well as to explore innovative immunotherapeutic strategies to lower the tumor microenvironment barrier. Topics of interest include but are not limited to immunotherapy and combination therapy against brain malignant tumors as well as basic research that improves the understanding and treatment of brain tumors. We welcome manuscripts from the following subtopics:
1, Mechanisms of malignant brain tumor (especially high-grade glioma) microenvironment components affecting the immune system and/or immunotherapeutic response.
2, Innovative immunotherapy strategies against brain malignant tumor.
3, Methods of targeting tumor microenvironment or counteracting the immunosuppression to improve immunotherapeutic responses of brain tumors
4, Clinical trial of advanced immunotherapy treatment on brain tumors (e.g., CAR-T, TCR-T, oncolytic virus, tumor vaccine, combination studies, etc)
NOTE: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation are considered out of the scope of this section. Experimental validations using cell lines only are not acceptable either.
